For the best experience use Mini app app on your smartphone
FDA's Vinay Prasad resigned after backlash over pausing Sarepta's Elevidys gene therapy, following deaths linked to treatment. Critics accused him of restricting access to a life-saving drug. Sarepta later resumed shipments for ambulatory patients only. Retail sentiment turned 'extremely bullish' on Stocktwits despite the stock's 87% YTD drop.
short by / 10:51 am on 30 Jul
For the best experience use inshorts app on your smartphone